ProKidney Corp
Change company Symbol lookup
Select an option...
PROK ProKidney Corp
PGNRF Pan Global Resources Inc
GLDD Great Lakes Dredge & Dock Corp
CLVT Clarivate PLC
WTER Alkaline Water Company Inc
DSL DoubleLine Income Solutions Fund
GCO Genesco Inc
MPAA Motorcar Parts of America Inc
FMCKL Federal Home Loan Mortgage Corp
FNHC Fednat Holding Co
Go

Company profile

ProKidney Corp., formerly Social Capital Suvretta Holdings Corp. III, is a clinical-stage biotechnology company. The Company is focused on developing a cell therapy platform capable of treating multiple chronic kidney diseases (CKD) using a patient’s own cells isolated from the patient intended for treatment. Its lead product candidate, Renal Autologous Cell Therapy (REACT), is designed to stabilize or improve kidney function in a CKD patient's diseased kidneys. REACT is a product that includes selected renal cells (SRCs) prepared from a patient’s own, autologous, renal cells. The Company is focused on conducting a Phase III development program and multiple Phase II clinical trials for REACT in subjects with moderate to severe diabetic kidney disease.

The symbol you entered, DNAC, changed to PROK.

Price
Delayed
$7.53
Day's Change
0.105 (1.42%)
Bid
--
Ask
--
B/A Size
--
Day's High
7.83
Day's Low
7.30
Volume
(Heavy Day)

Today's volume of 66,286 shares is on pace to be much greater than PROK's 10-day average volume of 40,399 shares.

66,286
Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

The risk of loss in trading futures can be substantial. Clients must consider all relevant risk factors, including their own personal financial situation, before trading. Margin and level 2 options approval or higher is required. Not all account owners will qualify.

Dividends are converted to USD using the current rate of exchange at the end of the business day on the day the dividend went EX. Earnings are converted to USD using the current rate of exchange at the end of the business day on the day earnings were announced.

Copyright © 2022. All rights reserved.

Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.

Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.